172 related articles for article (PubMed ID: 27863037)
1. Multivalent Aptamer-RNA Conjugates for Simple and Efficient Delivery of Doxorubicin/siRNA into Multidrug-Resistant Cells.
Jeong H; Lee SH; Hwang Y; Yoo H; Jung H; Kim SH; Mok H
Macromol Biosci; 2017 Apr; 17(4):. PubMed ID: 27863037
[TBL] [Abstract][Full Text] [Related]
2. Multivalent comb-type aptamer-siRNA conjugates for efficient and selective intracellular delivery.
Yoo H; Jung H; Kim SA; Mok H
Chem Commun (Camb); 2014 Jun; 50(51):6765-7. PubMed ID: 24830507
[TBL] [Abstract][Full Text] [Related]
3. Quick synthesis of a novel combinatorial delivery system of siRNA and doxorubicin for a synergistic anticancer effect.
Chen M; Wang L; Wang F; Li F; Xia W; Gu H; Chen Y
Int J Nanomedicine; 2019; 14():3557-3569. PubMed ID: 31190812
[No Abstract] [Full Text] [Related]
4. Reversing of multidrug resistance breast cancer by co-delivery of P-gp siRNA and doxorubicin via folic acid-modified core-shell nanomicelles.
Wu Y; Zhang Y; Zhang W; Sun C; Wu J; Tang J
Colloids Surf B Biointerfaces; 2016 Feb; 138():60-9. PubMed ID: 26655793
[TBL] [Abstract][Full Text] [Related]
5. Reversal of multidrug resistance in vitro by co-delivery of MDR1 targeting siRNA and doxorubicin using a novel cationic poly(lactide-co-glycolide) nanoformulation.
Misra R; Das M; Sahoo BS; Sahoo SK
Int J Pharm; 2014 Nov; 475(1-2):372-84. PubMed ID: 25178825
[TBL] [Abstract][Full Text] [Related]
6. Multifunctional QD-based co-delivery of siRNA and doxorubicin to HeLa cells for reversal of multidrug resistance and real-time tracking.
Li JM; Wang YY; Zhao MX; Tan CP; Li YQ; Le XY; Ji LN; Mao ZW
Biomaterials; 2012 Mar; 33(9):2780-90. PubMed ID: 22243797
[TBL] [Abstract][Full Text] [Related]
7. Multifunctional aptamer-based nanoparticles for targeted drug delivery to circumvent cancer resistance.
Liu J; Wei T; Zhao J; Huang Y; Deng H; Kumar A; Wang C; Liang Z; Ma X; Liang XJ
Biomaterials; 2016 Jun; 91():44-56. PubMed ID: 26994877
[TBL] [Abstract][Full Text] [Related]
8. Aptamer-functionalized hybrid nanoparticle for the treatment of breast cancer.
Powell D; Chandra S; Dodson K; Shaheen F; Wiltz K; Ireland S; Syed M; Dash S; Wiese T; Mandal T; Kundu A
Eur J Pharm Biopharm; 2017 May; 114():108-118. PubMed ID: 28131717
[TBL] [Abstract][Full Text] [Related]
9. Lanthanide-integrated supramolecular polymeric nanoassembly with multiple regulation characteristics for multidrug-resistant cancer therapy.
Jin W; Wang Q; Wu M; Li Y; Tang G; Ping Y; Chu PK
Biomaterials; 2017 Jun; 129():83-97. PubMed ID: 28329693
[TBL] [Abstract][Full Text] [Related]
10. Polyamidoamine dendrimers-based nanomedicine for combination therapy with siRNA and chemotherapeutics to overcome multidrug resistance.
Pan J; Mendes LP; Yao M; Filipczak N; Garai S; Thakur GA; Sarisozen C; Torchilin VP
Eur J Pharm Biopharm; 2019 Mar; 136():18-28. PubMed ID: 30633973
[TBL] [Abstract][Full Text] [Related]
11. Integrated hollow mesoporous silica nanoparticles for target drug/siRNA co-delivery.
Ma X; Zhao Y; Ng KW; Zhao Y
Chemistry; 2013 Nov; 19(46):15593-603. PubMed ID: 24123533
[TBL] [Abstract][Full Text] [Related]
12. Improvement in the drug delivery and anti-tumor efficacy of PEGylated liposomal doxorubicin by targeting RNA aptamers in mice bearing breast tumor model.
Moosavian SA; Abnous K; Badiee A; Jaafari MR
Colloids Surf B Biointerfaces; 2016 Mar; 139():228-36. PubMed ID: 26722819
[TBL] [Abstract][Full Text] [Related]
13. Aptamer-Based Erythrocyte-Derived Mimic Vesicles Loaded with siRNA and Doxorubicin for the Targeted Treatment of Multidrug-Resistant Tumors.
Wang T; Luo Y; Lv H; Wang J; Zhang Y; Pei R
ACS Appl Mater Interfaces; 2019 Dec; 11(49):45455-45466. PubMed ID: 31718159
[TBL] [Abstract][Full Text] [Related]
14. A nuclear targeted Dox-aptamer loaded liposome delivery platform for the circumvention of drug resistance in breast cancer.
Li X; Wu X; Yang H; Li L; Ye Z; Rao Y
Biomed Pharmacother; 2019 Sep; 117():109072. PubMed ID: 31202169
[TBL] [Abstract][Full Text] [Related]
15. Reversal of multidrug resistance by small interfering RNA (siRNA) in doxorubicin-resistant MCF-7 breast cancer cells.
Dönmez Y; Gündüz U
Biomed Pharmacother; 2011 Mar; 65(2):85-9. PubMed ID: 21237614
[TBL] [Abstract][Full Text] [Related]
16. A self-assembled polyjuglanin nanoparticle loaded with doxorubicin and anti-Kras siRNA for attenuating multidrug resistance in human lung cancer.
Wen ZM; Jie J; Zhang Y; Liu H; Peng LP
Biochem Biophys Res Commun; 2017 Dec; 493(4):1430-1437. PubMed ID: 28958938
[TBL] [Abstract][Full Text] [Related]
17. Smart ligand: aptamer-mediated targeted delivery of chemotherapeutic drugs and siRNA for cancer therapy.
Li X; Zhao Q; Qiu L
J Control Release; 2013 Oct; 171(2):152-62. PubMed ID: 23777885
[TBL] [Abstract][Full Text] [Related]
18. Epithelial cell adhesion molecule aptamer conjugated PEG-PLGA nanopolymersomes for targeted delivery of doxorubicin to human breast adenocarcinoma cell line in vitro.
Alibolandi M; Ramezani M; Sadeghi F; Abnous K; Hadizadeh F
Int J Pharm; 2015 Feb; 479(1):241-51. PubMed ID: 25529433
[TBL] [Abstract][Full Text] [Related]
19. Multivalent aptamer-modified tetrahedral DNA nanocage demonstrates high selectivity and safety for anti-tumor therapy.
Han X; Jiang Y; Li S; Zhang Y; Ma X; Wu Z; Wu Z; Qi X
Nanoscale; 2018 Dec; 11(1):339-347. PubMed ID: 30534748
[TBL] [Abstract][Full Text] [Related]
20. A controllable aptamer-based self-assembled DNA dendrimer for high affinity targeting, bioimaging and drug delivery.
Zhang H; Ma Y; Xie Y; An Y; Huang Y; Zhu Z; Yang CJ
Sci Rep; 2015 May; 5():10099. PubMed ID: 25959874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
